Heatwurx Inc. (NASDAQ:PCSA) Short Interest Down 69.3% in January

Heatwurx Inc. (NASDAQ:PCSA) was the recipient of a significant drop in short interest in January. As of January 15th, there was short interest totaling 30,093 shares, a drop of 69.3% from the December 31st total of 98,000 shares. Approximately 1.4% of the shares of the company are short sold. Based on an average daily volume of 114,015 shares, the short-interest ratio is currently 0.3 days. Based on an average daily volume of 114,015 shares, the short-interest ratio is currently 0.3 days. Approximately 1.4% of the shares of the company are short sold.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the company. Wall Street Zen raised Heatwurx from a “sell” rating to a “hold” rating in a report on Saturday, January 3rd. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Heatwurx in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $25.00.

Heatwurx Stock Performance

PCSA stock traded down $0.04 during trading on Wednesday, hitting $3.16. 14,348 shares of the company traded hands, compared to its average volume of 90,043. The company has a 50-day moving average of $4.62 and a 200-day moving average of $5.77. Heatwurx has a 1 year low of $2.74 and a 1 year high of $20.22. The firm has a market capitalization of $7.15 million, a PE ratio of -0.09 and a beta of 1.13.

Heatwurx (NASDAQ:PCSA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($1.75) EPS for the quarter, topping analysts’ consensus estimates of ($2.00) by $0.25. Sell-side analysts expect that Heatwurx will post -4.05 EPS for the current year.

Heatwurx Company Profile

Processa Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine that has completed Phase 1b clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers.